1. Home
  2. BOLT vs AMS Comparison

BOLT vs AMS Comparison

Compare BOLT & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

N/A

Current Price

$3.28

Market Cap

7.3M

Sector

Health Care

ML Signal

N/A

Logo American Shared Hospital Services

AMS

American Shared Hospital Services

HOLD

Current Price

$1.50

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOLT
AMS
Founded
2015
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
11.1M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
BOLT
AMS
Price
$3.28
$1.50
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$34.00
N/A
AVG Volume (30 Days)
21.3K
15.0K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,695,000.00
$19,714,000.00
Revenue This Year
N/A
$6.93
Revenue Next Year
$133.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.07
0.81
52 Week Low
$3.13
$1.25
52 Week High
$7.20
$3.11

Technical Indicators

Market Signals
Indicator
BOLT
AMS
Relative Strength Index (RSI) 34.35 49.89
Support Level N/A $1.37
Resistance Level $4.46 $1.75
Average True Range (ATR) 0.22 0.08
MACD -0.06 0.01
Stochastic Oscillator 20.59 27.78

Price Performance

Historical Comparison
BOLT
AMS

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

About AMS American Shared Hospital Services

American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.

Share on Social Networks: